Esperion Therapeutis.Inc. sell Bank of America Co.
Summary
This prediction is currently active. The prediction for Esperion Therapeutis.Inc. shows a convincing performance of -16.38%. This prediction currently runs until 20.06.25. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | 31.456% | 31.456% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
15.06.23
15.06.24
16.06.24